Kestra Medical Technologies (NASDAQ:KMTS) Stock Rating Upgraded by Wall Street Zen

Key Points

• Kestra Medical Technologies has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, indicating a shift in analyst sentiment regarding the stock.
• Wells Fargo reduced its price target for **Kestra Medical Technologies** from $28.00 to $27.00, while the average consensus price target currently stands at $27.33.
• Institutional investors are actively purchasing shares, with notable investments occurring from firms such as **Omega Fund Management**, amounting to approximately $44.75 million in the first quarter.

Wall Street Zen upgraded shares of Kestra Medical Technologies (NASDAQ:KMTS - Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Separately, Wells Fargo & Company decreased their target price on shares of Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating for the company in a research note on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Kestra Medical Technologies presently has an average rating of "Moderate Buy" and an average price target of $27.33.

Kestra Medical Technologies Stock Down 0.5%

KMTS stock traded down $0.12 during trading on Friday, hitting $25.43. The stock had a trading volume of 47,090 shares, compared to its average volume of 284,791. The company's 50 day moving average price is $17.53 and its two-hundred day moving average price is $20.02. Kestra Medical Technologies has a 1-year low of $13.25 and a 1-year high of $27.71. The company has a current ratio of 6.84, a quick ratio of 6.84 and a debt-to-equity ratio of 0.23.

Hedge Funds Weigh In On Kestra Medical Technologies

Several institutional investors have recently bought and sold shares of KMTS. Yu Fan bought a new position in Kestra Medical Technologies in the first quarter valued at $56,880,000. T. Rowe Price Investment Management Inc. bought a new stake in Kestra Medical Technologies in the 1st quarter worth approximately $56,613,000. Omega Fund Management LLC bought a new stake in Kestra Medical Technologies in the 1st quarter worth approximately $44,754,000. Alliancebernstein L.P. purchased a new position in shares of Kestra Medical Technologies during the 1st quarter worth $29,500,000. Finally, Eventide Asset Management LLC boosted its stake in shares of Kestra Medical Technologies by 285.7% during the 2nd quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company's stock worth $17,584,000 after acquiring an additional 785,557 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.